Firebrick Pharma to Brief Investors After Nasodine Approval and $1.5m Placement

The latest announcement is out from Firebrick Pharma Limited ( (AU:FRE) ).

Firebrick Pharma will host an investor webinar on 27 April 2026 to brief shareholders and potential investors on recent developments, including the approval of its Nasodine Nasal Spray in Indonesia and completion of a $1.5 million placement. The session, presented by Executive Chair Dr Peter Molloy, will be accessible live and via replay online, offering stakeholders an opportunity to gain deeper insight into the company’s growth trajectory and commercialisation plans for its povidone-iodine product portfolio.

By highlighting new market approvals and fresh capital, the webinar underscores Firebrick’s ongoing expansion in key international markets and its efforts to strengthen investor engagement. The combination of regulatory progress and additional funding signals a continued push to scale distribution of Nasodine-branded products, which may enhance the company’s competitive position in the respiratory health segment and support its broader commercial strategy.

More about Firebrick Pharma Limited

Firebrick Pharma Limited is an Australian pharmaceutical company focused on developing and commercialising novel formulations and uses of povidone-iodine. Its lead product, Nasodine Nasal Spray, has been introduced in the United States, Singapore, and Fiji & the South Pacific, with regulatory efforts ongoing in markets such as the Philippines. The company has also launched Nasodine Throat Spray as a follow-on product in Singapore and Fiji, targeting broader respiratory health applications in international markets.

Average Trading Volume: 91,873

Technical Sentiment Signal: Sell

Current Market Cap: A$18.37M

See more data about FRE stock on TipRanks’ Stock Analysis page.